A Randomized, Single-Blind, Placebo-Controlled, Single-Centre, Phase 1Study in Healthy Volunteers to Assess the Safety, Tolerability andPharmacokinetics of AZD4017 After Single Ascending Oral Doses.
Phase of Trial: Phase I
Latest Information Update: 17 Jun 2009
At a glance
- Drugs AZD 4017 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 17 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Nov 2008 New trial record.